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 Molecular radiotheragnostics directly links nuclear medicine 
diagnostic imaging to therapy. The imaging study is used 
to detect a speciﬁc molecular target associated with a 
disease process. A radiotherapeutic molecule with a similar 
biodistribution to the diagnostic agent can then be used to 
deliver targeted therapy. 
 Molecular radiotheragnostics have been applied to manage 
both benign and malignant thyroid disease since the 1940s. 
The speciﬁ c molecular pathway targeted is the sodium/iodide 
symporter (NIS) located on the basolateral membrane of the 
thyroid follicular cell. Radiolabelling of iodide or a similar ion 
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allows targeting of the NIS system with radiopharmaceuticals 
for imaging ( 123 I-radioiodine and  99m Tc-pertechnetate) and 
treatment ( 131 I-radioiodine) by virtue of their gamma ray and 
beta-particle emissions, respectively. 
 Scintigraphic imaging directly guides  131 I-radioiodine treat-
ment planning to maximise therapeutic beneﬁ t while minimis-
ing adverse reactions, in a personalised medicine approach. 
 Principles 
 Molecular radiotheragnostics combine nuclear medicine 
diagnostic imaging with treatment. Imaging is used to detect 
a specific molecular target associated with an underlying 
disease process. A radiotherapeutic molecule with a similar 
biodistribution to the imaging radiopharmaceutical can then 
be used to deliver targeted therapy. 1 
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 Molecular radiotheragnostics have been applied to thyroid 
disease since the 1940s when radioiodine was first used to treat 
thyroid disorders. 1 Subsequent gamma camera development in 
the 1950s then made imaging possible. 2 The specific molecular 
pathway targeted is the sodium/iodide symporter (NIS). NIS-
mediated iodide accumulation within the thyroid is central 
to molecular thyroid theragnostics. Radiolabelling of iodide 
or similar ions allows targeting of the NIS-system for imaging 
and therapy. 1 
 The sodium/iodide symporter 
 Iodine is essential for the synthesis of the thyroid hormones 
thyroxine (T4) and triiodothyronine (T3). Iodide ions are taken 
up by the NIS, a basolateral transmembrane protein on the 
thyroid follicular cells that actively co-transports sodium and 
iodide ions into cells against a concentration gradient. 3 Iodide is 
then translocated across the apical cell membrane and oxidised 
by thyroid peroxidase. Iodination of the tyrosine residues of 
thyroglobulin (colloid protein) then takes place (organification). 
Thyroglobulin is the precursor of thyroid hormone synthesis. 
 NIS expression is upregulated by thyroid-stimulating 
hormone (TSH) and downregulated by thyroglobulin and anti-
thyroid medications. NIS is also expressed by non-thyroidal 
tissues, eg salivary and lacrimal glands, stomach, lactating 
breast, placenta, kidneys and thymus. 4,5 
 Thyroid theragnostic radiopharmaceuticals 
 Theragnostic radiopharmaceuticals emit ionising radiation 
as gamma rays and/or beta-particles, allowing scintigraphic 
imaging and therapy, respectively (Table  1 ). The NIS-system 
can be targeted specifically using radioactive iodide (I) or 
pertechnetate ions, which share similar chemical properties. 
Labelled with the gamma-emitter technetium-99m ( 99m Tc), 
pertechnetate ions are taken up via the NIS into thyroid 
follicular cells where they are trapped but not organified. 6 
 99m Tc-pertechnetate is the first-line scintigraphic diagnostic 
thyroid imaging agent for the investigation of benign thyroid 
disease, is readily available and is inexpensive. Reduced NIS 
expression by malignant thyroid cells leads to low pertechnetate 
uptake, giving a ‘cold nodule’ appearance. 
 123 I-radioiodine decays by gamma ray emission and, unlike 
pertechnetate, is organified by the thyroid so can be used to 
characterise poorly functioning retrosternal thyroid tissue, for 
thyroid cancer imaging and for personalised treatment dose 
planning. Disadvantages include the relative cost, availability 
and 13-hour half-life. 
 131 I-radioiodine has an 8-day half-life and decays by gamma 
ray and beta-particle emission allowing both imaging and 
targeted therapy.  131 I beta particles travel only short distances 
through tissue (average 0.4 mm) and cause cell death directly 
by radiation-induced DNA damage or indirectly through free-
radical formation. 
 Benign thyroid disease 
 Molecular radiotheragnostics in benign thyroid disease are 
applied in the imaging and treatment of 
 >  hyperthyroidism due to solitary toxic nodule, toxic multi-
nodular goitre or Graves’ disease (relapsed or fi rst-line 
treatment) 
 >  large non-toxic goitre to reduce gland volume in non-surgical 
candidates. 7 
 Scintigraphic imaging with  99m Tc-pertechnetate or, less 
frequently, radioiodine provides visual assessment of activity 
distribution within the thyroid reflecting physiological and 
pathophysiological NIS-mediated iodide uptake. Imaging 
confirms the cause of hyperthyroidism and can be used to 
assess feasibility of  131 I as a therapeutic option and to guide 
activity prescription. 
 Anti-thyroid drugs, exogenous iodine, thyroxine and 
amiodarone all interfere with NIS-mediated thyroid 
radiopharmaceutical uptake and are withheld for varying 
periods before imaging (Table  2 ). 8 Uptake of activity reflects 
metabolic function and may be quantified as a percentage of the 
administered activity to guide treatment. 
 Amplified follicular cell NIS expression in Graves’ disease 
results in globally increased iodide uptake, shown as diffuse, 
increased radiopharmaceutical activity throughout the gland 
on imaging. Toxic multi-nodular glands show increased NIS 
expression in ‘hot’ hyperfunctioning nodules and reduced 
levels in ‘cold’ nodules. Increased NIS levels in autonomously 
functioning nodules manifest as increased radiopharmaceutical 
uptake within the nodule (Fig  1 ). 9 
 Following the same NIS-uptake pathway,  131 I can be used to 
deliver targeted beta-particle therapy. Treatment aims are to 
cure hyperthyroidism and achieve a euthyroid or hypothyroid 
state. 7,10 UK guidelines recommend fixed treatment activities 
between 400 and 800 MBq depending on gland size, underlying 
aetiology and patient comorbidities. In practice, most patients 
receive 400–600 MBq. 11 
 Thyroid function is usually controlled with anti-thyroid 
drugs before treatment to reduce the risk of ‘thyroid storm’ 
 Key points 
 Molecular radiotheragnostics use nuclear medicine diagnostic 
imaging to detect a speciﬁc molecular target. A radiotherapeutic 
molecule with a similar bio-distribution can then be used to 
deliver targeted therapy 
 In thyroid disease, the speciﬁc molecular pathway targeted is 
the sodium/iodide symporter (NIS) 
 NIS-mediated iodide (or a similar ion) accumulation within the 
thyroid is central to molecular theragnostics in both benign and 
malignant thyroid disease 
 99 m Tc-pertechnetate and  123 I-radioiodine are used for imaging 
and  131 I-radioiodine for treatment.  99m Tc-pertechnetate is not 
the imaging agent of choice for thyroid cancer imaging 
 Imaging is useful to plan therapy and optimise a personalised 
medicine approach 
 KEYWORDS: 99mTc-pertechnetate, DTC (differentiated thyroid 
cancer), molecular, NIS (sodium/iodide symporter), radioiodine, 
radiotheragnostic, thyroid, thyrotoxicosis ■ 
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following therapy. These drugs should be withdrawn a few days 
before treatment because of their theoretical radio-protective 
effects. 7 In patients with poorly functioning, non-toxic goitre, 
recombinant TSH is occasionally used to upregulate NIS and 
enhance  131 I uptake. 
 Although radioiodine treatment for benign thyroid disease is 
outpatient based, patients are requested to follow simple radiation 
protection restrictions post-treatment. These are related to the 
activity of radioiodine received and may include a period of time 
off work depending on the nature of work, travel restrictions and 
avoidance of prolonged close contact with children and pregnant 
women. Premenopausal women should also avoid pregnancy for 
6 months following radioiodine treatment. 11 
 Fixed activity regimens offer the advantage of ease of clinical 
prescription, outcomes with respect to euthyroidism and 
hypothyroidism being dose dependent. Lower administered 
activities may reduce risks of hypothyroidism but carry an 
increased risk of treatment failure. Dosimetric approaches 
aiming to calculate a ‘personalised’ therapeutic dose of  131 I 
to achieve euthyroidism have not yet been shown to improve 
outcomes. 12 
 Malignant thyroid disease 
 Molecular radiotherapy plays a pivotal role in radio-sensitive 
differentiated papillary and follicular thyroid cancer (DTC) 
treatment. 13 Thyroid cancer may present clinically as a nodule 
or, increasingly, as an incidental imaging finding. While thyroid 
nodules are common, thyroid cancer is rare (UK incidence 
3.4×10 3 cases/annum). 14,15 
 Table 1.  Properties of thyroid theragnostic radiopharmaceuticals 
Properties Radiopharmaceutical 
  131 I-radioiodine  123 I-radioiodine  99m Tc-pertechnetate 
Production Reactor Cyclotron Generator
Half-life 8 days (long half-life allows 
transport some distance from 
production)
13 hours (longer half-life 
allows transport some 
distance from production)
6 hours  ( short half-
life favours on site 
production)
Radioactive method of decay Gamma ray and beta particles Gamma ray Gamma ray
Gamma ray energy peak  (140 KeV = ideal peak 
for gamma camera imaging) 
364 KeV 159 KeV 140 KeV
Availability and expense Easily available, cheap Less readily available 
expensive
Readily available, 
cheap
Radiation burden High Low Lowest
Uses Imaging and therapy Imaging Imaging
Uptake mechanism Physiological: both trapped 
and organified
Physiological: both trapped 
and organified
Mimics iodide: Trapped 
but not organified
Imaging time after diagnostic dose administration 18–24 hours (post-therapy 
imaging at 1–5 days)
2–6 hours and 18–24 hours 20 minutes
Potential for stunning Yes No No
A B
 Fig 1.  Scintigraphic imaging 
reﬂ ecting physiological and 
pathophysiological NIS-
mediated iodide uptake in 
Graves’ disease (A) and a toxic 
nodule (B). 
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 DTCs are characterised by slow growth and favourable 
prognosis (80–95% 10-year survival). Local disease recurrence 
in the thyroid surgical bed, cervical nodes or distant metastases 
is reported in 5–20% of patients, depending on primary 
staging, histological subtype and nodal involvement at 
diagnosis. 16 
 Surgery and  131 I therapy are the cornerstones of DTC 
management. Following total thyroidectomy, usually with 
loco-regional node dissection,  131 I is recommended to ablate 
normal thyroid remnant tissue, improve local disease control, 
increase the specificity of thyroglobulin (marker of tumour 
recurrence) and enable whole-body scintigraphy to identify 
occult metastases. TSH stimulation is used to upregulate 
NIS and maximise  131 I uptake, either by post-thyroidectomy 
levothyroxine withdrawal or using recombinant human TSH. 13 
 Fixed activities are prescribed to ablate the thyroid remnant 
while minimising the risk of inducing a secondary cancer. 
Following publication of the HiLo study, the recommended 
activity for remnant ablation in the UK is 1.1 GBq for low-
risk patients. Higher activities may be agreed for high-risk 
patients (nodal or distant metastases, extra-thyroidal tumour 
extension, R1 resection (microscopic residual tumour at the 
surgical resection margin) or primary tumour size >4 cm)
following multidisciplinary meeting discussion. 17 American 
and European guidelines recommend activities of 1.1–5.5 GBq 
for the treatment of metastases. 13,18 
 Post-ablation  131 I imaging performed 1–5 days post-treatment 
is used to confirm remnant thyroid uptake and detect iodine-
avid metastases. Tomographic imaging fused with CT (single 
photon emission computerised tomography (SPECT)-CT), 
increases lesion detection sensitivity and provides accurate 
anatomical localisation. Having commenced post-ablation 
levothyroxine replacement to achieve TSH suppression, 
subsequent monitoring usually relies on ultrasound and 
thyroglobulin measurement. Further cycles of therapeutic  131 I 
may be required to treat persisting iodine-avid metastases. 
 Diagnostic  123 I scintigraphy is sometimes helpful to 
detect occult disease, post thyroid remnant ablation, where 
other imaging has failed to identify the source of a rising 
thyroglobulin level.  123 I avoids the risk of ‘stunning’ and is 
preferred to  131 I in patients who might proceed to further 
radioiodine treatment. Increasingly, however,  123 I has been 
superseded by  18 F-fluorodeoxyglucose (FDG) positron 
emission tomography (PET)-CT in patients with increasing 
thyroglobulin and non-iodine avid disease to exclude surgically 
resectable disease, followed by empirical  131 I treatment. 
 Two-thirds of patients with metastatic disease become 
refractory to radioiodine because of tumour de-differentiation 
resulting in decreased NIS expression and/or targeting 
secondary to genetic alterations and dysregulation of signalling 
pathways. 19 De-differentiated, recurrent iodine-negative lesions 
tend to have high glycolytic rates and are therefore FDG-avid. 
This inverse relationship between iodine and FDG-avidity 
(Fig  2 ), depending on differentiation, probably reflects tumour 
heterogeneity and importantly may result in a poor response to 
 131 I treatment. Positive NIS-immunostaining could predict  131 I 
accumulation and, therefore, the effectiveness of treatment in 
recurrent lesions. 20 
 Advances in molecular biology have identified specific 
molecular kinase pathways where oncogenic mutations have 
resulted in reduced NIS expression/targeting. 21 Tyrosine kinase 
inhibitors (eg sorafenib) block these pathways, increasing NIS 
expression. The mitogen-activated protein kinase pathway 
inhibitor sulemetinib has also been shown to promote  131 I 
uptake in a small series of patients with iodine-refractory 
thyroid cancer, but this requires confirmation in larger studies. 22 
 Re-differentiation therapies (eg retinoic acid) upgrade NIS 
and may restore  131 I avidity. In some non-iodine avid thyroid 
 Table 2.  Guidance times for withholding substances 
that may interfere with NIS-mediated thyroid radio-
pharmaceutical uptake prior to imaging 
Interfering substance Recommended time to withhold 
prior to imaging 
 Anti-thyroid drugs  Pertechnetate imaging 
Can be continued  123 I or  131 I 2–4 days 
 Thyroxine (T 4 ) therapy  4–6 weeks 
 Triiodothyronine (T 3 ) 
therapy 
 2 weeks 
 Exogenous iodine (eg 
water-soluble iodinated 
contrast) 
 6–8 weeks 
 Amiodarone  Greater than 6 months 
 Adapted from Balon  et al. 8 
A B
 Fig 2.  Inverse relationship 
 between iodine and FDG avidity – 
a reﬂ ection of  tumour 
differentiation. A –  131 I-radioiodine 
anterior neck image shows no 
iodine avid disease within the neck 
(salivary gland and nasal uptake is 
physiological); B –  18 F-FDG PET-CT 
coronal fused image shows bilateral 
FDG-avid neck disease. CT = 
computerised tomography; FDG = 
ﬂ uorodeoxyglucose; PET = positron 
emission tomography 
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cancers the problem lies in NIS cell membrane translocation. 
Enhancing this may aid therapeutic  131 I uptake. 19 An alternative 
approach lies in detailed dosimetry planning to deliver a 
prescribed tumour radiation dose. Considering anatomical 
and uptake characteristics of each malignant lesion, dosimetry-
based planning offers the opportunity to optimise treatment 
on an individual patient-basis, rather than administering fixed 
 131 I activities. SPECT-CT technology is critical to undertaking 
3-dimensional absorbed-dose calculations. 
 Future directions 
 124 I is currently the only positron-emitting radioisotope of iodine 
that may have a role in molecular thyroid radiotheragnostics in 
the future.  124 I-PET-CT has the potential advantage of superior 
image quality and might allow more accurate quantification to 
optimise prescribed amounts of therapeutic  131 I. 
 Tumour heterogeneity, oxygenation and cell kinetics all 
affect dose-response relationships. Tumour apoptosis, hypoxia 
and cellular proliferation may be assessed by radioactive 
tracers, such as  99m Tc-annexin V,  18 F-fluoromisonidazole and 
 18 F-fluorothymidine, and used to predict therapeutic response 
to  131 I. 
 Conclusions 
 The established role of nuclear medicine imaging and 
therapy in managing benign and malignant thyroid disease 
is the oldest and, arguably, most successful example of 
molecular radiotheragnostics. The future lies in advances in 
molecular biology, the development of agents that increase 
NIS expression, dosimetry-based treatment planning and 
the introduction of novel PET radiopharmaceuticals, all of 
which have the potential to deliver the goal of a personalised 
medicine approach to thyroid disease. ■ 
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